Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subject: VEN

Helix to Advance and Scale Viral Early Warning Efforts with Financial Support from The Rockefeller Foundation


SAN MATEO, Calif. and NEW YORK, Dec. 23, 2021 /PRNewswire/ -- The Rockefeller Foundation's Pandemic Prevention Institute (PPI) announced today that it will provide funding to Helix, a leader in nationwide viral surveillance for SARS-CoV-2, to rapidly advance infrastructure, data systems and technology needed to further scale and connect genomic surveillance to a broader network for improved outcomes. This collaboration helps address the national need for faster, more comprehensive and consistent viral sequencing in the service of public health.

Rockefeller Foundation funding enables Helix to rapidly advance genomic surveillance efforts around viral threats.

"Omicron's rapid spread continues to highlight the need for durable pathogen surveillance capabilities that will allow local communities to prepare for and prevent pandemic outbreaks," said Dr. Rick Bright, senior vice president of Pandemic Prevention and Response at The Rockefeller Foundation and CEO of the Pandemic Prevention Institute. "Helix's ability to deploy, coordinate and deliver the latest laboratory and data capabilities for national viral surveillance illustrates the importance of public-private partnerships in pandemic prevention efforts now and in the future." 

Viral surveillance through genetic epidemiology ? a tool that leverages next-generation sequencing (NGS) to track the transmission and emergence patterns of viral variant types ? has increasingly been deployed to track COVID-19. By using NGS for SARS-CoV-2 and future respiratory pathogens, public health leaders will be able to flag emerging outbreaks to inform public health guidance and tailor local policy to prevent regional outbreaks before they spread.

"We are excited to partner with the Pandemic Prevention Institute to develop sustainable data generation and exchange technologies for improved pathogen surveillance," said Dr. James Lu, CEO and co-founder of Helix. "These capabilities are indispensable today for COVID-19 and will similarly be essential for monitoring other respiratory pathogens like pandemic influenza. Accelerating new technologies will enable provider systems and public health to rethink how they care for their populations."

Since the winter of 2020, Helix, in partnership with the Centers for Disease Control and Prevention (CDC), has been utilizing its next-generation sequencing capability to contribute to national surveillance efforts. Through its public viral surveillance dashboard and routine data sharing, Helix regularly provides reporting to state public health, health systems and other health care institutions. Helix has published over a dozen pre-print and peer-reviewed publications on viral sequences, several of which were among the first to accurately predict a variant's spread across the United States.

This collaboration will support the development of increased viral surveillance capabilities for respiratory illnesses, initially at five health systems, including several dedicated to supporting underserved communities across the United States. This is an important step in bringing laboratories and data capabilities together to advance the global goal of ending the current pandemic and preventing future ones.

About Helix
Helix is the leading population genomics company operating at the intersection of clinical care, research, and genomics. Its end-to-end platform enables health systems, life sciences companies and payers to advance genomic research and accelerate the integration of genomic data into clinical care. Helix, with the support of the NIH RADx-ATP program currently operates one of the largest and most capable labs performing high-throughput diagnostic PCR testing in the U.S. and provides nationwide viral surveillance to meet the needs of health systems, employers, governments and organizations across the country. Learn more at www.helix.com/.

About The Pandemic Prevention Institute
The Pandemic Prevention Institute is mission-driven to contribute to the crucial work of building systems that detect, prevent and mitigate pandemic threats, leading to rapid, effective containment. The PPI is pursuing its mission through the integration of cutting-edge technology and analytic approaches that turn data into action that drives life-saving decisions; a federated network of data users and holders with global representation; and collaborative leadership at the global level. For information on partners, data solutions and more visit www.rockefellerfoundation.org/pandemicpreventioninstitute/ and follow us on Twitter @PPI_Insights.

About The Rockefeller Foundation
The Rockefeller Foundation is a pioneering philanthropy built on collaborative partnerships at the frontiers of science, technology, and innovation to enable individuals, families, and communities to flourish. We work to promote the well-being of humanity and make opportunity universal. Our focus is on scaling renewable energy for all, stimulating economic mobility, and ensuring equitable access to healthy and nutritious food. For more information, sign up for our newsletter at rockefellerfoundation.org and follow us on Twitter @RockefellerFdn. 

Contact Us 
Helix
[email protected]

The Rockefeller Foundation 
[email protected]

SOURCE Helix


These press releases may also interest you

at 08:40
The "Global Cell Counting Market: Analysis By Product, By Application, By End-User, By Region Size, Trends and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The global cell counting market was valued at US$9.98...

at 06:15
The "Global Immune Health Supplements Market - Outlook & Forecast 2023-2028" report has been added to  ResearchAndMarkets.com's offering. The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach...

at 05:45
The Gross Law Firm issues the following notice to shareholders of Amplitude, Inc. . Shareholders who purchased shares of AMPL during...

at 05:45
The Gross Law Firm issues the following notice to shareholders of Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II ....

at 05:30
The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to...

at 05:00
The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering....



News published on and distributed by: